JUN and neoplasm: At the topical tumor site, local immune activation by IMQ stimulates c-Jun/AP-1 signaling in IFN-I primed and TLR7-expressing DCs to produce interleukin (IL)-12, which impairs tumor-associated angiogenesis and induces necrosis at the treated site.